Regentis Biomaterials (NYSE American: RGNT) is developing a cell-free, off-the-shelf hydrogel implant called GelrinC that is designed to regenerate knee cartilage. According to a recent article, the implant gradually resorbs over approximately six to nine months as new tissue fills the treated area. This approach aims to provide durable, long-term treatment outcomes in orthopedic medicine.
In a Pilot/Phase II study, GelrinC demonstrated 100% greater pain improvement compared with traditional microfracture treatment. Additionally, 24-month follow-up results showed a mean MOCART score of 88.8 out of 100, an MRI-based measure of cartilage repair quality. These results suggest that GelrinC may offer a more effective solution for cartilage repair than existing methods.
The company has received a CE mark in Europe, providing a pathway for commercialization in that market. Regentis is also advancing its pivotal Phase III clinical study in the United States and preparing for the FDA’s Premarket Approval process. The company is working to complete enrollment in its U.S. study and expand commercialization efforts, with a focus on developing cartilage repair solutions intended to deliver lasting improvements in pain and mobility.
GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. This represents a significant opportunity for Regentis, as the demand for effective cartilage repair solutions continues to grow. The company’s Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone.
For more information on Regentis Biomaterials, visit their client page. The full article can be viewed at https://ibn.fm/cTSlo. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. as part of a paid investor awareness and marketing engagement. MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries, as well as article and editorial syndication to 5,000+ outlets.
